By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Tax Strategy & Growth Planning · Los Angeles, CA | Published July 2026 | Cannabis Advisory
Cannabis marketing deductions are one of the most significant practical changes qualifying medical cannabis operators can implement immediately following the April 22 rescheduling. Under 280E, marketing and advertising expenses at the retail stage were entirely non-deductible. A dispensary spending $150,000 annually on digital marketing, SEO, social media, events, and promotions received zero federal tax benefit from that spending. Post-rescheduling, qualifying medical operators can deduct every dollar of that spend as an ordinary business expense under IRC Section 162. Moreover, because Treasury has announced that 280E relief applies to the full 2026 tax year, the deduction covers the period from January 1, not just from April 22 forward. For adult-use operators, by contrast, nothing has changed. 280E still applies, and marketing remains non-deductible.
QUICK ANSWER
Qualifying medical cannabis operators can now deduct marketing and advertising expenses as ordinary business expenses under IRC Section 162. At a 35% effective rate, a dispensary spending $150,000 per year on marketing captures approximately $52,500 in annual federal tax savings. Adult-use operators remain subject to 280E and cannot deduct marketing expenses. Two important constraints apply: dual-license operators must allocate marketing between medical and adult-use activities using a documented methodology, and state advertising restrictions are entirely separate from federal deductibility and remain unchanged.
Cannabis Marketing Deductions After Rescheduling: At a Glance
- What changed: Marketing and advertising expenses at the retail stage shift from entirely non-deductible under 280E to fully deductible as ordinary business expenses under IRC Section 162 for qualifying medical cannabis operators.
- Who it applies to: State-licensed medical cannabis operators qualifying for Schedule III treatment under the April 22 order. Adult-use operators remain subject to 280E, no change.
- Key constraint for dual-license operators: Marketing that supports medical activities is deductible. Marketing for adult-use activities is still non-deductible. The allocation requires documentation and a defensible methodology.
- What does not change: State advertising restrictions on cannabis marketing. Rescheduling affected federal tax treatment only. State rules apply exactly as before.
- Implementation requirement: The accounting reclassification is not automatic. Marketing expense accounts must be explicitly reclassified from 280E-disallowed SG&A to Section 162 ordinary business expenses in your accounting system.
- GreenGrowth's role: We review marketing expense classifications for qualifying medical clients and implement the accounting changes needed to capture the full deduction. Book a marketing tax review →
What Marketing Expenses Are Now Deductible for Medical Cannabis Operators
Under IRC Section 162, ordinary and necessary business expenses are deductible. For qualifying medical cannabis operators, this now covers virtually every line item in a standard dispensary marketing budget. The requirement is that each expense be ordinary (common in the industry), necessary (appropriate for the business), and paid or incurred during the taxable year.
The Full List of Newly Deductible Marketing Categories
Digital advertising, including Google Ads, Meta Ads, and programmatic display, is now deductible. Additionally, SEO and content marketing costs, including website development, blog content, and search optimization, qualify. Social media marketing, whether organic or paid, is covered. Email marketing platforms and campaign costs are included, as are print and out-of-home advertising such as billboards, mailers, and in-store promotional materials.
Beyond the digital categories, event marketing and sponsorships are deductible. Public relations and media relations costs qualify under Section 162. Photography and video production for marketing purposes is covered, as are marketing agency retainers and consulting fees. Promotions and discounts, within applicable state rules, are also deductible as ordinary business expenses.
One nuance is specific to cannabis: the IRS has not yet issued formal guidance on cannabis marketing deductions post-rescheduling. Consequently, any marketing expenditure that appears primarily to promote adult-use activities rather than medical activities could draw scrutiny, particularly in dual-license operations. Document the business purpose of each significant marketing expenditure now, before the IRS develops specific examination frameworks for these deductions.
💬 The Conversation Worth Having
When marketing was non-deductible under 280E, the after-tax cost of every marketing dollar was the full dollar. There was no tax offset. As a result, many medical dispensaries were systematically under-investing in marketing because the economic cost was higher than it looked. Post-rescheduling, each marketing dollar now costs a qualifying medical operator $0.65 after tax, not $1.00. That change in after-tax economics should directly affect budget decisions. A dispensary that spent $100,000 on marketing when it was fully non-deductible should now be willing to spend roughly $154,000 to achieve the same after-tax cost -- and potentially reach many more customers in the process.
Has your accounting system been updated to reflect post-rescheduling marketing deductibility? If not, we can fix that before Q4.
Book a Review →How to Implement Marketing Deductions in Your Cannabis Accounting System
The deductibility change does not apply itself automatically. Three specific accounting actions are required for qualifying medical cannabis operators: reclassifying marketing expense accounts, updating the chart of accounts for dual-license operations, and rebuilding the tax projection to reflect the new deductibility in estimated tax calculations.
Step 1: Reclassify Marketing Expense Accounts
Operators whose QuickBooks or accounting platform was configured to treat all retail-stage expenses as 280E-disallowed will continue classifying marketing as non-deductible until the configuration changes explicitly. The reclassification moves marketing accounts from the 280E-disallowed SG&A bucket to Section 162 ordinary business expenses. Document the date this change was made. Include a note in your accounting system explaining the legal basis: April 22, 2026 rescheduling order plus Treasury's announced full-year transition rule for the 2026 tax year.
Step 2: Allocate Marketing for Dual-License Operations
For operators with both medical and adult-use licenses, the allocation question is critical. Marketing that serves both segments from a shared budget requires a defensible methodology for determining how much is attributable to each. Percentage of medical versus adult-use revenue, percentage of medical versus adult-use customer transactions, or square footage allocated to each segment are examples of objectively measurable bases. An undocumented allocation will not survive IRS examination. In addition, operators should update the chart of accounts to maintain separate marketing expense lines for each segment. This makes the allocation visible, trackable, and auditable from the first transaction.
Step 3: Update the Tax Projection
After reclassifying marketing in the accounting system, rebuild the 2026 tax projection to reflect the additional deductible expense. Marketing expenses now reduce taxable income, which in turn reduces both the annual tax liability and the Q3 and Q4 estimated tax payments. Operators who have already recalculated their estimated payments for the broader 280E relief may need to run the calculation again if significant marketing spend was not included in the initial recalculation. For more on how we approach this as part of post-rescheduling planning, see our cannabis advisory services.
▶ Documentation Checklist: What to Maintain for Marketing Deductions
Per-Expense Documentation
- Vendor invoices and payment records organized by expense type and date
- Agency or vendor contracts describing scope of services
- Business purpose note for each significant expenditure
- For dual-license: notation of which segment the expense serves
System and Policy Documentation
- Updated chart of accounts showing reclassification from 280E SG&A to Section 162, with dated notation of when the change was made
- Written allocation methodology document for dual-license operators
- Annual marketing budget approved in writing with spending by category
- Updated tax projection reflecting marketing deductibility
State Advertising Restrictions: Separate From Federal Deductibility
The most common point of confusion we encounter on post-rescheduling marketing questions is between federal tax deductibility and state advertising restrictions. These are entirely separate legal frameworks. A state that restricts cannabis advertising within 1,000 feet of a school, prohibits certain promotional materials, or requires health warnings on all cannabis advertisements is enforcing state-level regulations that have no connection to federal tax law.
What Rescheduling Did and Did Not Change
The April 22 rescheduling changed the federal tax treatment of marketing expenses for qualifying medical operators. It did not change any state's cannabis advertising regulations. A medical dispensary in California can now deduct its advertising expenses federally, but the advertising itself must still comply with California's cannabis advertising rules. Similarly, in states where cannabis advertising faces broad restrictions, those restrictions remain fully in place under state law regardless of federal rescheduling status. Review your marketing programs for state compliance separately from the federal deductibility question. Both issues affect the financial viability of cannabis marketing investment, but the analysis and the governing law are different for each.
Should Medical Cannabis Operators Increase Marketing Spend Post-Rescheduling?
Yes, and this is one of the most underappreciated financial implications of rescheduling for medical dispensaries. When marketing was non-deductible under 280E, the after-tax cost of each marketing dollar was the full dollar. There was no tax benefit offsetting the spend. Post-rescheduling, however, the after-tax cost of each marketing dollar for a qualifying medical operator at a 35% effective rate is $0.65. The 35% deduction effectively reduces the net cost.
The Budget Implication
This change in after-tax economics should directly affect budget decisions. A medical operator that was spending $100,000 per year on marketing when it was fully non-deductible should therefore be willing to spend approximately $154,000 to achieve the same after-tax cost and potentially reach significantly more patients. Operators who do not revisit their marketing budgets in light of this change are leaving growth opportunity on the table. The planning window for 2026 marketing investment that captures the full-year deduction closes December 31. For a comprehensive review of what your cannabis tax compliance picture looks like post-rescheduling, our advisory team works through the full set of newly available deductions, including marketing, for qualifying medical clients.
KEY TAKEAWAYS
- ›Qualifying medical cannabis operators can now deduct all marketing and advertising expenses as ordinary business expenses under IRC Section 162, covering the full 2026 tax year under Treasury's announced transition rule.
- ›A medical dispensary spending $150,000 per year on marketing captures approximately $52,500 in annual federal tax savings at a 35% effective rate. Adult-use operators remain subject to 280E. Marketing is still non-deductible for them.
- ›The accounting reclassification is not automatic. Marketing expense accounts must be explicitly moved from the 280E-disallowed SG&A bucket to Section 162 in your accounting system, with the change dated and documented.
- ›Dual-license operators must allocate marketing expenses between medical and adult-use activities using a documented, objectively measurable methodology. An undocumented allocation will not survive IRS examination.
- ›State advertising restrictions remain unchanged. Rescheduling affected federal tax treatment only. Comply with your state's cannabis advertising rules exactly as before.
- ›The after-tax cost of each marketing dollar for qualifying medical operators is now 35% lower. Medical operators who do not revisit their marketing budgets in light of this change are leaving growth opportunity behind.
Frequently Asked Questions
Qualifying medical cannabis operators can now deduct marketing and advertising expenses as ordinary business expenses under IRC Section 162, following the April 22, 2026 rescheduling of medical cannabis to Schedule III. Under 280E, these expenses were entirely non-deductible at the retail stage. Adult-use cannabis operators remain subject to 280E and cannot deduct marketing expenses. Their tax treatment is unchanged from prior law.
The deduction applies to the full 2026 tax year under Treasury's announced transition rule, not just from April 22 forward. However, implementing it requires an explicit accounting reclassification. The deductibility does not apply automatically once the legal right exists. Your accounting system must be updated to reflect the change.
Under IRC Section 162, any ordinary and necessary marketing or advertising expense is now deductible for qualifying medical operators. This includes digital advertising (Google Ads, Meta Ads, programmatic), SEO and content marketing, social media marketing, email marketing, print and out-of-home advertising, event marketing and sponsorships, public relations, photography and video production for marketing, and marketing agency and consulting fees.
The expenses must be ordinary (common in the industry), necessary (appropriate for the business), and paid or incurred during the taxable year. The IRS has not yet issued specific guidance on cannabis marketing deductions post-rescheduling, so documenting the business purpose for each significant expenditure is important, particularly for dual-license operations where medical and adult-use activities share marketing resources.
Dual-license cannabis operators must allocate marketing expenses between their medical segment (deductible under Section 162) and their adult-use segment (still subject to 280E and non-deductible). The allocation must use an objectively measurable, documented methodology. Examples include percentage of medical versus adult-use revenue, percentage of medical versus adult-use customer transactions, or square footage allocated to each segment.
An undocumented or subjective allocation will not hold up under IRS examination. Additionally, the accounting system should maintain separate marketing expense lines for each segment so the allocation is visible, trackable, and auditable from the first transaction. Document the methodology in writing and review it at least annually as the revenue and transaction mix between segments changes.
No. State advertising restrictions on cannabis are imposed under state law and are entirely separate from federal tax deductibility. The April 22 rescheduling changed the federal tax treatment of marketing expenses for qualifying medical operators. It did not change any state's cannabis advertising regulations. Dispensaries must continue complying with their state's specific cannabis advertising rules regardless of rescheduling status.
Review your marketing programs for state compliance separately from the federal deductibility question. Both issues affect the financial viability of cannabis marketing investment, but the analysis is different for each. Federal deductibility determines your after-tax cost. State compliance determines what advertising you can legally run.
A qualifying medical cannabis dispensary spending $150,000 per year on marketing can save approximately $52,500 in federal income taxes annually at a 35% effective tax rate. This is the difference between $0 in deductions under 280E and a full $150,000 ordinary business expense deduction under Section 162. The savings applies to the full 2026 tax year under Treasury's announced transition rule.
Furthermore, the after-tax cost of each marketing dollar for a qualifying medical operator at 35% is now $0.65, not $1.00. This change in after-tax economics means operators can spend more on marketing for the same after-tax cost, or maintain the same spend level and capture the tax savings directly. Both approaches are rational depending on market conditions and growth priorities.
We review your current marketing expense classifications and confirm whether your accounting system is correctly configured to capture post-rescheduling deductibility. For operators still classifying marketing as non-deductible SG&A, we implement the reclassification and update the chart of accounts with dated documentation of the change and its legal basis.
For dual-license operators, we build the documented expense allocation methodology between medical and adult-use marketing activities and integrate it into the ongoing bookkeeping process. We also update the 2026 tax projection and Q3 and Q4 estimated payment calculations to reflect the additional deductible marketing spend. To start, book a cannabis marketing tax review.
Find Out What Marketing Deductions Your Cannabis Business Can Now Take
GreenGrowth CPAs reviews your current marketing expense classification, implements the accounting reclassification, and updates your 2026 tax projection to capture the full benefit of post-rescheduling marketing deductibility. We work with qualifying medical operators across California, New York, New Jersey, Minnesota, and Delaware.
KEY NUMBERS
Your Marketing Budget Just Got 35% Cheaper After Tax. Act on It Before Year-End.
Book a cannabis marketing tax review. We will confirm your deductibility status, implement the accounting reclassification, and help you think through whether your 2026 marketing budget reflects the new after-tax economics.
Book Your Free CFO Discovery Call →GreenGrowth CPAs · Cannabis Advisory Team
